CGP 40116

Drug Profile

CGP 40116

Latest Information Update: 28 Jan 1997

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-ischaemics; Antiepileptic drugs; Neuroprotectants; Nootropics
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Craniocerebral trauma; Epilepsy; Stroke

Most Recent Events

  • 28 Jan 1997 Discontinued-I for Head injuries in Switzerland (PO)
  • 28 Jan 1997 Discontinued-I for Stroke in Switzerland (PO)
  • 07 Jun 1995 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top